| First Author | Zhou J | Year | 2023 |
| Journal | Neuropharmacology | Volume | 226 |
| Pages | 109397 | PubMed ID | 36623805 |
| Mgi Jnum | J:332834 | Mgi Id | MGI:7428246 |
| Doi | 10.1016/j.neuropharm.2022.109397 | Citation | Zhou J, et al. (2023) AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease. Neuropharmacology 226:109397 |
| abstractText | We recently reported that the "Dopamine Neuron Challenge Test" (DNC Test), a diagnostic method that measures the levels of dopamine metabolites in cerebrospinal fluid (CSF) and plasma samples after pharmacologically inducing a transient dopamine release, can detect early-stage Parkinson's disease (PD) with high sensitivity and selectivity in mouse models. The use of haloperidol in the original DNC test to challenge dopamine neurons was less than ideal, as it may cause extrapyramidal motor symptoms. Here we report an improved DNC Test, in which the original challenging agents, haloperidol and methylphenidate, are replaced by a single challenging agent, a dopamine autoreceptor preferring antagonist AJ76 or UH232. We show that the improved DNC Test can achieve the same level of sensitivity and selectivity in detecting early PD in a mouse model without causing motor side effects. These findings significantly improve the practicality of using the DNC Test as a screening or diagnostic test for detecting early-stage PD in the high-risk population in humans. |
